Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 4/20 | 0.54 |
| ▸ | PDE1A | P54750 | 3/20 | 0.54 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.54 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.38 |
| ▸ | CBFB | Q13951 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | CLK2 | P49760 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7039414 | 0.90 | PDE9A (0.59) | PDE9APDE1APDE1BPDE1CPOLB | |
| SCHEMBL6371987 | 0.87 | PDE9A (0.40) | PDE9APDE1APDE1BPDE1CCYP11B1 | |
| SCHEMBL6366070 | 0.87 | PDE9A (0.44) | PDE9APDE1APDE1BPDE1CCYP11B1 | |
| SCHEMBL3494974 | 0.87 | AR (0.41) | PDE9APDE1APDE1BPDE1CIDO1 | |
| SCHEMBL3493363 | 0.85 | PDE9A (0.55) | PDE9APDE1APDE1BPDE1CCYP11B1 | |
| SCHEMBL6367719 | 0.82 | CACNA1H (0.39) | PDE9APDE1APDE1BPDE1CCYP11B1 | |
| SCHEMBL7039453 | 0.80 | PDE9A (0.61) | PDE9APDE1APDE1BPDE1CPOLB | |
| SCHEMBL5067594 | 0.79 | PDE9A (0.60) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6368276 | 0.78 | PIM1 (0.39) | IDO1LRRK2BTKCLK2CLK3 | |
| SCHEMBL6372381 | 0.78 | NTRK1 (0.41) | IDO1LRRK2KMT2ABTKCLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1440073-A1 | PDE9 INHIBITORS FOR TREATING CARDIOVASCULAR DISORDERS | Pfizer Limited (GB) | 2004-07-28 | — | — | EP | claimed |
| US-20030195205-A1 | PDE9 inhibitors for treating cardiovascular disorders | PFIZER INC. | 2003-10-16 | — | — | US | claimed |
| WO-2003037899-A1 | PDE9 INHIBITORS FOR TREATING CARDIOVASCULAR DISORDERS | PFIZER LIMITED (GB) | 2003-05-08 | — | — | WO | claimed |
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2123301-A1 | THERAPEUTIC AGENT FOR URINARY TRACT DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-6967204-B2 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC | 2005-03-31 | — | — | US | disclosed |
| EP-1440073-A1 | PDE9 INHIBITORS FOR TREATING CARDIOVASCULAR DISORDERS | Pfizer Limited (GB) | 2004-07-28 | — | — | EP | disclosed |
| US-20040023989-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | FRYBURG DAVID A (US) | 2004-02-05 | — | — | US | disclosed |
| US-20030195205-A1 | PDE9 inhibitors for treating cardiovascular disorders | PFIZER INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003037899-A1 | PDE9 INHIBITORS FOR TREATING CARDIOVASCULAR DISORDERS | PFIZER LIMITED (GB) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | BPHL, PDE12, UROD | PDE9A 6/4885PDE1A 44/4885PDE1B 41/4885 |
| US-20030195205-A1 | PDE9 inhibitors for treating cardiovascular disorders | PDE9A, PDE2A, PDE3A | PDE9A 1/4885PDE1A 62/4885PDE1B 50/4885 |
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | GPR119, PDE2A, PDE9A | PDE9A 3/4885PDE1A 46/4885PDE1B 39/4885 |
| US-20040023989-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | GPR119, PDE2A, PDE9A | PDE9A 3/4885PDE1A 46/4885PDE1B 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.